Stock Earnings

Question 1

What are Nykode Therapeutics ASA's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Nykode Therapeutics ASA has a total asset of $153, Net loss of $-38

Question 2

What are the key financial ratios for VACBF?

Accepted Answer

Nykode Therapeutics ASA's Current ratio is 9, has a Net margin is -475, sales per share of $0.02.

Question 3

How is Nykode Therapeutics ASA's revenue broken down by segment or geography?

Accepted Answer

Nykode Therapeutics ASA largest revenue segment is Novel Vaccines and Immunotherapies, at a revenue of 136,380,103 in the most earnings release.For geography, United States is the primary market for Nykode Therapeutics ASA, at a revenue of 136,380,103.

Question 4

Is Nykode Therapeutics ASA profitable?

Accepted Answer

no, according to the latest financial statements, Nykode Therapeutics ASA has a net loss of $-38

Question 5

Does Nykode Therapeutics ASA have any liabilities?

Accepted Answer

yes, Nykode Therapeutics ASA has liability of 17

Question 6

How many outstanding shares for Nykode Therapeutics ASA?

Accepted Answer

Nykode Therapeutics ASA has a total outstanding shares of 326.54

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	7	8	12	7	33	215
Revenue Growth (YoY)	-30%	-33%	71%	-79%	-85%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	25	31	28	18	17	16
Research & Development	--	--	29	26	16	10
Operating Expenses	48	55	69	57	41	33
Other Non Operating Income (Expenses)	--	0	0	0	0	0
Pretax Income	-32	-45	-44	-50	-11	180
Income Tax Expense	-7	-6	-8	-8	-1	31
Net Income	-25	-38	-35	-42	-9	149
Net Income Growth	-36%	9%	-17%	367%	-106%	-1,246%
Shares Outstanding (Diluted)	326.54	326.54	300.52	290.11	286.34	296.14
Shares Change (YoY)	9%	9%	4%	1%	-3%	438.99%
EPS (Diluted)	-0.07	-0.11	-0.11	-0.14	-0.03	0.5
EPS Growth	-42%	2%	-21%	348%	-107%	-303%
Free Cash Flow	-47	-51	-98	-23	0	180
Free Cash Flow Per Share	-0.14	-0.15	-0.32	-0.07	0	0.6
Gross Margin	--	--	--	--	--	--
Operating Margin	-571.42%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
Profit Margin	-357.14%	-475%	-291.66%	-600%	-27.27%	69.3%
Free Cash Flow Margin	-671.42%	-637.5%	-816.66%	-328.57%	0%	83.72%
EBITDA	-38	-45	-54	-49	-7	181
EBITDA Margin	-542.85%	-562.5%	-450%	-700%	-21.21%	84.18%
D&A For EBITDA	2	2	2	1	0	0
EBIT	-40	-47	-56	-50	-7	181
EBIT Margin	-571.42%	-587.5%	-466.66%	-714.28%	-21.21%	84.18%
Effective Tax Rate	21.87%	13.33%	18.18%	16%	9.09%	17.22%

Nykode Therapeutics ASA (VACBF) Price

VACBF Stock Price Chart

VACBF Income

Follow-Up Questions